Malignant brain tumour in 4 year old boy treated at Gleneagles Global Health City

Malignant brain tumour in 4 year old boy treated at Gleneagles Global Health City

Malignant brain tumour in 4 year old boy treated at Gleneagles Global Health City

Chennai, June 12, 2019: A 4 year old boy from Sudan was recently treated at Gleneagles Global Health City for a Medulloblastoma, the most commonly seen malignant brain tumour in children. The child had been suffering fro m symptoms of headache, vomiting and impaired balance for duration of two months. Initial investigations done at a hospital in Sudan showed a large tumour in the posterior fossa, i.e. the back of the brain, which is suggestive of a medulloblastoma with hydrocephalus. Hydrocephalus is a condition in which the accumulation of excess cer ebrospinal fluid (CSF) in the brain causes a variety of symptoms including repeated, often severe vomiting, let hargy and headaches that frequently occur in the morning and improve as the day goes on.He underwent a ven triculoperitoneal shunt in Sudan to help relieve the pressure on the brain caused by fluid accumulation. This primarily treated the hydrocephalus. After this, the child was brought to Chennai for a surgery to remove his brain tumour.

Dr Nigel Symss, Senior Consultant Neurosurgeon and Functional Neurosurgeon, Gleneagles Global Health City, Chennai said,”Medulloblastomas occur in two million people per year, and affect children 10 times more than adults. These tumours are the second-most frequent brain tumour in children after pilocytic astrocytoma, and the most common malignant brain tumour in children, comprising nearly 14 % of newly diagnosed brain tumo urs. They are invasive, rapidly growing tumours that spread through the cerebrospinal fluid and metastasize to different locations along the surface of the brain and spinal cord.”

On arrival, the child was seen by a team of neurosurgeons, paediatrician and neuro anaesthetist. A MRI scan of the brain and spine, blood tests, ECG and other tests were ordered. The MRI of the brain reconfirmed the pre sence of a large tumour in the posterior fossa. There was no spread of tumour to the spine. His parents were counselled about the need for a major brain surgery to remove the tumour, and the potential risks and compl ications of surgery.

The child underwent amid line posterior fossa craniotomy which involves removing a small part of the skull at the back of the head, to gain access to the tumour. Using sophisticated and advanced equipment like the opera ting microscope, CUSA (cavitron ultrasonic surgical aspirator), and intraoperative Navigation, it was possible to remove the whole tumour. The surgery lasted nearly 6 to 7 hours as the tumour was very large and had to be deli cately separated from the nerves and major blood vessels of the brain. The use of microscope, CUSA and navigat ion makes surgical removal of such tumours safer and with minimal complications.

After surgery the child was managed in the neuro intensive care by a specialised team of intensivists. He was la ter shifted to the ward where he underwent rehabilitation. Two weeks after his surgery he was found to have we akness of all four limbs. The MRI scan of the spine showed the tumour had spread to the cervical spine. He wa s started on cranio spinal radiotherapy by a team of Radiation Oncologists. He gradually improved in his limb we akness, and is currently undergoing rehabilitation. The latest MRI scan of the brain and spine after radiother apy showed no recurrence of the tumour and the spinal metastasis had regressed. He is now awaiting chemother ap y.

Dr Nigel Symss, further added, “The mainstay of treatment for brain tumours is surgery. In benign tumours, sur gery may be the only treatment required. However with cancerous tumours follo wing surgery, children more tha n 3 years may also require adju vant therapy with radiation and chemotherapy. This may increase chances of a dis ease-free survival. This combination of treatment may permit a 5-year survival in nearly 80% of cases.” It is said that the outcome is possibly inferior if the child is less than 3 years old, degree of resection is inadequate, or if an y CSF, spinal, other part of brain, or systemic spread occurs. The parents need to be coun selled about the nature of the disease and their support is mandatory in the long term management of children with these tumours.

Gleneagles Global Healthy City, Chennai has long been at the forefront of integrated neuro care. The hospital drives a multi-disciplinary approach to brain tumour care with a team of neurosurgeons, neuro anaesthes iol ogists, neuro radiologists, neuro pathologists, radiation and medical oncologists, neuro rehabilitation team, as well as the neuro nurses working as a single team. Couple of years back, the hospital launched a Brain Tumour Support Group called ‘CONNECT’- a platform for patients suffering from brain tumours, to share their expe rie nces, ideas and also provide emotional support. Gleneagles Global Health City via ‘CONNECT’ has also been co ntinually raising efforts to spread awareness amongst general physicians and caregivers about the manage ment protocols that are available to battle brain tumours.

About Gleneagles Global Health City, Chennai:

Gleneagles Global Health City, the sprawling 21-acre facility located in Perumbakkam, Chennai is the largest fa cility of Gleneagles Global Hospitals India. With a capacity of over 1000 beds and accreditations from leading agencies, the facility is Asia’s most trusted and leading Multi-Organ Transplant Centre. The hospital has unde rt aken several path-breaking Liver, Neuro, Heart, Lung and Kidney procedures. It is recognized by several inter national and national level accrediting agencies. World-class infrastructure, dedicated staff and a commitment for medical excellence are the USPs of this facility. The hospital has several achievements to its credit and contin ues to work on several pioneering procedures.

Gleneagles Global Hospitals has multi-super speciality hospitals in Bengaluru, Hyderabad, Chennai and Mumbai. The brand is the most preferred hospital group for multi-organ transplants in Asia region. The parent entity of Gl eneagles Global Hospitals is IHH Healthcare, a leading premium integrated healthcare provider with a net wo rk of 84 hospitals and more than 16,000 licensed beds. It is one of the largest healthcare groups in the world by market capitalisation and is listed in the Main Market of Bursa Malaysia and Main Board of SGX-ST. IHH is a lea ding player in the home markets of Malaysia, Singapore, Turkey and India, and in their key growth markets of Chi na and Hong Kong. 

Website: http://gleneaglesglobalhospitals.com/